[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2007",
          "fs": "Feb 2007",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe22AF"
          },
          "Id": "a0POZ00000WwQe22AF",
          "Event_Date__c": "2007-02-19",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "Feb 2007",
          "Status_History__c": "a132P000000ApB2QAK"
        },
        "change": null
      }
    ],
    "dateString": "Feb 2007",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Mar 2009",
          "fs": "Mar 2009",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe32AF"
          },
          "Id": "a0POZ00000WwQe32AF",
          "Event_Date__c": "2009-03-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Mar 2009",
          "Status_History__c": "a132P000000ApOnQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "fs": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Mar 2009",
          "fs": "Mar 2009",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Analgesic Subcommittee at meeting Thursday 12 March 2009.",
          "fs": "Clinical advice received from Analgesic Subcommittee at meeting Thursday 12 March 2009.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe42AF"
          },
          "Id": "a0POZ00000WwQe42AF",
          "Event_Date__c": "2009-03-12",
          "Event_Description__c": "Clinical advice received from Analgesic Subcommittee at meeting Thursday 12 March 2009.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "High",
          "Formatted_Date__c": "Mar 2009",
          "PTAC_Comments__c": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "Status_History__c": "a132P000000ApP6QAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2009",
          "fs": "May 2009",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe62AF"
          },
          "Id": "a0POZ00000WwQe62AF",
          "Event_Date__c": "2009-05-07",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "High",
          "Formatted_Date__c": "May 2009",
          "Status_History__c": "a132P000000ApQjQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "No Formal Recommendation",
          "fs": "No Formal Recommendation",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-analgesic-subcommittee-minutes-2010-04.pdf \" target=\"_blank\">Analgesic Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-analgesic-subcommittee-minutes-2010-04.pdf \" target=\"_blank\">Analgesic Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2010",
          "fs": "Apr 2010",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Analgesic Subcommittee at meeting Thursday 29 April 2010.",
          "fs": "Clinical advice received from Analgesic Subcommittee at meeting Thursday 29 April 2010.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe82AF"
          },
          "Id": "a0POZ00000WwQe82AF",
          "Event_Date__c": "2010-04-29",
          "Event_Description__c": "Clinical advice received from Analgesic Subcommittee at meeting Thursday 29 April 2010.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-analgesic-subcommittee-minutes-2010-04.pdf \" target=\"_blank\">Analgesic Subcommittee minutes</a>",
          "Outcome__c": "No Formal Recommendation",
          "Formatted_Date__c": "Apr 2010",
          "Status_History__c": "a132P000000ApZ5QAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2010",
          "fs": "Jun 2010",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe92AF"
          },
          "Id": "a0POZ00000WwQe92AF",
          "Event_Date__c": "2010-06-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Jun 2010",
          "Status_History__c": "a132P000000ApbEQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Decline",
          "fs": "Decline",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf \" target=\"_blank\">PTAC minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf \" target=\"_blank\">PTAC minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2011",
          "fs": "Aug 2011",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeA2AV"
          },
          "Id": "a0POZ00000WwQeA2AV",
          "Event_Date__c": "2011-08-11",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf \" target=\"_blank\">PTAC minutes</a>",
          "Outcome__c": "Decline",
          "Formatted_Date__c": "Aug 2011",
          "Status_History__c": "a132P000000ApsZQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "Discussed in &#39;Correspondence/Matters Arising&#39; following the publication of Janet Hardy&#39;s study. The Committee&#39;s previous recommendation to decline &#39;remained unchanged&#39;.",
          "fs": "Discussed in &#39;Correspondence/Matters Arising&#39; following the publication of Janet Hardy&#39;s study. The Committee&#39;s previous recommendation to decline &#39;remained unchanged&#39;.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Decline",
          "fs": "Decline",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2012-11.pdf\" target=\"_blank\">PTAC minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2012-11.pdf\" target=\"_blank\">PTAC minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2012",
          "fs": "Nov 2012",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeB2AV"
          },
          "Id": "a0POZ00000WwQeB2AV",
          "Event_Date__c": "2012-11-08",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2012-11.pdf\" target=\"_blank\">PTAC minutes</a>",
          "Outcome__c": "Decline",
          "Summary__c": "Discussed in &#39;Correspondence/Matters Arising&#39; following the publication of Janet Hardy&#39;s study. The Committee&#39;s previous recommendation to decline &#39;remained unchanged&#39;.",
          "Formatted_Date__c": "Nov 2012",
          "Status_History__c": "a132P000000AqE2QAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2019",
          "fs": "Nov 2019",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeD2AV"
          },
          "Id": "a0POZ00000WwQeD2AV",
          "Event_Date__c": "2019-11-28",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Nov 2019",
          "Status_History__c": "a132P000000BBVFQA4"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2019",
          "fs": "Nov 2019",
          "change": null
        },
        "Event_Description": {
          "s": "Assigned to Analgesic Subcommittee meeting to provide advice on Tuesday 3 December 2019",
          "fs": "Assigned to Analgesic Subcommittee meeting to provide advice on Tuesday 3 December 2019",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeE2AV"
          },
          "Id": "a0POZ00000WwQeE2AV",
          "Event_Date__c": "2019-11-28",
          "Event_Description__c": "Assigned to Analgesic Subcommittee meeting to provide advice on Tuesday 3 December 2019",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Nov 2019",
          "Status_History__c": "a132P000000BBVVQA4"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a number of applications had been received for ketamine for use in the palliative care setting. The Subcommittee noted there was some geographic variation in the origin of these applications. The Subcommittee considered this was likely due to limited evidence for its use and variations in expert opinion. The Subcommittee considered that some hospices may be funding the use of ketamine via private means outside of the Combined Pharmaceutical Budget (CPB) and that this may also be contributing to the geographic variation.</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there exists a high unmet health need for the small number of patients in the end of life setting who have intractable pain that is not responsive to conventional treatments. The Subcommittee considered that the unmet need is further confounded by national variability in access to interventional procedures for management of end of life pain. The Subcommittee noted that access to ketamine is available for patients in DHB hospitals and considered that there may be limited evidence for its use in the non-palliative care setting. The Subcommittee considered that funded access to ketamine should be made available for patients in the palliative care setting as well. </p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that PTAC had previously considered ketamine for intractable pain in the palliative care setting and had recommended it for decline at its meeting in August 2011. The Subcommittee noted that PTAC had reaffirmed the decline recommendation at its meeting in November 2012 following the publication of <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22965960\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012;30:3611-7</a> regarding burst ketamine therapy. The Subcommittee noted that PTAC had expressed comfort with the arrangement that patients requiring treatment with ketamine infusions go via the NPPA process. The Subcommittee considered that access to ketamine via Special Authority would be a more suitable pathway than via NPPA, and would likely improve equity of access. The Subcommittee considered that in many cases a patient would be deceased prior to a NPPA application being processed.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that additional evidence investigating the use of ketamine in intractable pain in palliative care was unlikely to be generated. </p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that ketamine be funded via Special Authority for the treatment of intractable pain for patients in the end of life setting, based on unmet health need and the suitability benefit regarding the timing of approval of funding in comparison to funding via NPPA.</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the number of patients accessing ketamine treatment was likely to be small; around 75 patients per year. The Subcommittee considered that in total patients would receive treatment for a maximum duration of one week, at an average dose of 0.1 mg/kg/hour, for an average total lifetime dose of 250 mg per patient. The Subcommittee considered that between 1/3 to 1/2 patients would stop treatment prematurely due to adverse events.\u00a0</p>",
          "fs": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a number of applications had been received for ketamine for use in the palliative care setting. The Subcommittee noted there was some geographic variation in the origin of these applications. The Subcommittee considered this was likely due to limited evidence for its use and variations in expert opinion. The Subcommittee considered that some hospices may be funding the use of ketamine via private means outside of the Combined Pharmaceutical Budget (CPB) and that this may also be contributing to the geographic variation.</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there exists a high unmet health need for the small number of patients in the end of life setting who have intractable pain that is not responsive to conventional treatments. The Subcommittee considered that the unmet need is further confounded by national variability in access to interventional procedures for management of end of life pain. The Subcommittee noted that access to ketamine is available for patients in DHB hospitals and considered that there may be limited evidence for its use in the non-palliative care setting. The Subcommittee considered that funded access to ketamine should be made available for patients in the palliative care setting as well. </p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that PTAC had previously considered ketamine for intractable pain in the palliative care setting and had recommended it for decline at its meeting in August 2011. The Subcommittee noted that PTAC had reaffirmed the decline recommendation at its meeting in November 2012 following the publication of <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22965960\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012;30:3611-7</a> regarding burst ketamine therapy. The Subcommittee noted that PTAC had expressed comfort with the arrangement that patients requiring treatment with ketamine infusions go via the NPPA process. The Subcommittee considered that access to ketamine via Special Authority would be a more suitable pathway than via NPPA, and would likely improve equity of access. The Subcommittee considered that in many cases a patient would be deceased prior to a NPPA application being processed.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that additional evidence investigating the use of ketamine in intractable pain in palliative care was unlikely to be generated. </p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that ketamine be funded via Special Authority for the treatment of intractable pain for patients in the end of life setting, based on unmet health need and the suitability benefit regarding the timing of approval of funding in comparison to funding via NPPA.</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the number of patients accessing ketamine treatment was likely to be small; around 75 patients per year. The Subcommittee considered that in total patients would receive treatment for a maximum duration of one week, at an average dose of 0.1 mg/kg/hour, for an average total lifetime dose of 250 mg per patient. The Subcommittee considered that between 1/3 to 1/2 patients would stop treatment prematurely due to adverse events.\u00a0</p>",
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>Regarding the Subcommittee\u2019s recommendation to fund ketamine via a Special Authority for the treatment of intractable pain in the end of life setting (paragraph 6.11), the Committee noted that it had considered an application for burst therapy in this context at its August 2011 and November 2012 meetings. </p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that it had <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf\" target=\"_blank\">recommended for decline</a>, on the basis of evidence of no difference in pain compared to standard care (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22965960\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012 Oct 10;30(29):3611-7</a>), and a higher risk of adverse events. The Committee noted that the Analgesic Subcommittee\u2019s recommendation pertained to continuous infusion therapy rather than burst therapy. </p><p>1.1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that there is an unmet need for patients with intractable pain in the end of life setting, in particular for patients with neuropathic pain who live in locations where they are unable to access a regional anaesthesia service in the community setting. </p><p>1.1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that in this context, continuous infusion in the end of life setting, ketamine could be used to reduce opioid requirements. </p><p>1.1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the Analgesic Subcommittee had not defined specific Special Authority criteria. </p><p>1.1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee was supportive of the Subcommittee\u2019s recommendation and considered that further advice could be sought from the Faculty of Pain Medicine (FPM) of the Australian and New Zealand College of Anaesthetists (ANZCA) and from palliative care clinicians regarding appropriate Special Authority criteria, the likely numbers of patients and duration of treatment. The Committee <b>recommended</b> that proposed Special Authority criteria be defined by the Analgesic Subcommittee, and reviewed by PTAC.</p>",
          "fs": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>Regarding the Subcommittee\u2019s recommendation to fund ketamine via a Special Authority for the treatment of intractable pain in the end of life setting (paragraph 6.11), the Committee noted that it had considered an application for burst therapy in this context at its August 2011 and November 2012 meetings. </p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that it had <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf\" target=\"_blank\">recommended for decline</a>, on the basis of evidence of no difference in pain compared to standard care (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22965960\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012 Oct 10;30(29):3611-7</a>), and a higher risk of adverse events. The Committee noted that the Analgesic Subcommittee\u2019s recommendation pertained to continuous infusion therapy rather than burst therapy. </p><p>1.1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that there is an unmet need for patients with intractable pain in the end of life setting, in particular for patients with neuropathic pain who live in locations where they are unable to access a regional anaesthesia service in the community setting. </p><p>1.1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that in this context, continuous infusion in the end of life setting, ketamine could be used to reduce opioid requirements. </p><p>1.1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the Analgesic Subcommittee had not defined specific Special Authority criteria. </p><p>1.1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee was supportive of the Subcommittee\u2019s recommendation and considered that further advice could be sought from the Faculty of Pain Medicine (FPM) of the Australian and New Zealand College of Anaesthetists (ANZCA) and from palliative care clinicians regarding appropriate Special Authority criteria, the likely numbers of patients and duration of treatment. The Committee <b>recommended</b> that proposed Special Authority criteria be defined by the Analgesic Subcommittee, and reviewed by PTAC.</p>",
          "change": null
        },
        "Outcome": {
          "s": "No Formal Recommendation",
          "fs": "No Formal Recommendation",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Mar 2020",
          "fs": "Mar 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Analgesic Subcommittee at meeting Tuesday 3 December 2019.",
          "fs": "Clinical advice received from Analgesic Subcommittee at meeting Tuesday 3 December 2019.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeF2AV"
          },
          "Id": "a0POZ00000WwQeF2AV",
          "Event_Date__c": "2020-03-03",
          "Event_Description__c": "Clinical advice received from Analgesic Subcommittee at meeting Tuesday 3 December 2019.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "No Formal Recommendation",
          "Formatted_Date__c": "Mar 2020",
          "Published_Discussion__c": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a number of applications had been received for ketamine for use in the palliative care setting. The Subcommittee noted there was some geographic variation in the origin of these applications. The Subcommittee considered this was likely due to limited evidence for its use and variations in expert opinion. The Subcommittee considered that some hospices may be funding the use of ketamine via private means outside of the Combined Pharmaceutical Budget (CPB) and that this may also be contributing to the geographic variation.</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there exists a high unmet health need for the small number of patients in the end of life setting who have intractable pain that is not responsive to conventional treatments. The Subcommittee considered that the unmet need is further confounded by national variability in access to interventional procedures for management of end of life pain. The Subcommittee noted that access to ketamine is available for patients in DHB hospitals and considered that there may be limited evidence for its use in the non-palliative care setting. The Subcommittee considered that funded access to ketamine should be made available for patients in the palliative care setting as well. </p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that PTAC had previously considered ketamine for intractable pain in the palliative care setting and had recommended it for decline at its meeting in August 2011. The Subcommittee noted that PTAC had reaffirmed the decline recommendation at its meeting in November 2012 following the publication of <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22965960\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012;30:3611-7</a> regarding burst ketamine therapy. The Subcommittee noted that PTAC had expressed comfort with the arrangement that patients requiring treatment with ketamine infusions go via the NPPA process. The Subcommittee considered that access to ketamine via Special Authority would be a more suitable pathway than via NPPA, and would likely improve equity of access. The Subcommittee considered that in many cases a patient would be deceased prior to a NPPA application being processed.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that additional evidence investigating the use of ketamine in intractable pain in palliative care was unlikely to be generated. </p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that ketamine be funded via Special Authority for the treatment of intractable pain for patients in the end of life setting, based on unmet health need and the suitability benefit regarding the timing of approval of funding in comparison to funding via NPPA.</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the number of patients accessing ketamine treatment was likely to be small; around 75 patients per year. The Subcommittee considered that in total patients would receive treatment for a maximum duration of one week, at an average dose of 0.1 mg/kg/hour, for an average total lifetime dose of 250 mg per patient. The Subcommittee considered that between 1/3 to 1/2 patients would stop treatment prematurely due to adverse events.\u00a0</p>",
          "PTAC_Comments__c": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>Regarding the Subcommittee\u2019s recommendation to fund ketamine via a Special Authority for the treatment of intractable pain in the end of life setting (paragraph 6.11), the Committee noted that it had considered an application for burst therapy in this context at its August 2011 and November 2012 meetings. </p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that it had <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf\" target=\"_blank\">recommended for decline</a>, on the basis of evidence of no difference in pain compared to standard care (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22965960\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012 Oct 10;30(29):3611-7</a>), and a higher risk of adverse events. The Committee noted that the Analgesic Subcommittee\u2019s recommendation pertained to continuous infusion therapy rather than burst therapy. </p><p>1.1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that there is an unmet need for patients with intractable pain in the end of life setting, in particular for patients with neuropathic pain who live in locations where they are unable to access a regional anaesthesia service in the community setting. </p><p>1.1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that in this context, continuous infusion in the end of life setting, ketamine could be used to reduce opioid requirements. </p><p>1.1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the Analgesic Subcommittee had not defined specific Special Authority criteria. </p><p>1.1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee was supportive of the Subcommittee\u2019s recommendation and considered that further advice could be sought from the Faculty of Pain Medicine (FPM) of the Australian and New Zealand College of Anaesthetists (ANZCA) and from palliative care clinicians regarding appropriate Special Authority criteria, the likely numbers of patients and duration of treatment. The Committee <b>recommended</b> that proposed Special Authority criteria be defined by the Analgesic Subcommittee, and reviewed by PTAC.</p>",
          "Status_History__c": "a132P000000BWiiQAG"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2022",
          "fs": "Apr 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeH2AV"
          },
          "Id": "a0POZ00000WwQeH2AV",
          "Event_Date__c": "2022-04-04",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Apr 2022",
          "Status_History__c": "a132P000000DfC5QAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2022",
          "fs": "Apr 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Assigned to Analgesic Advisory Committee meeting to provide advice on Thursday 5 May 2022",
          "fs": "Assigned to Analgesic Advisory Committee meeting to provide advice on Thursday 5 May 2022",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeI2AV"
          },
          "Id": "a0POZ00000WwQeI2AV",
          "Event_Date__c": "2022-04-20",
          "Event_Description__c": "Assigned to Analgesic Advisory Committee meeting to provide advice on Thursday 5 May 2022",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Apr 2022",
          "Status_History__c": "a132P000000Dxr4QAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">2022-05-05-Analgesics-Advisory-Committee-Record.pdf (pharmac.govt.nz)</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">2022-05-05-Analgesics-Advisory-Committee-Record.pdf (pharmac.govt.nz)</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2022",
          "fs": "Aug 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Analgesic Advisory Committee at meeting Thursday 5 May 2022.",
          "fs": "Clinical advice received from Analgesic Advisory Committee at meeting Thursday 5 May 2022.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeJ2AV"
          },
          "Id": "a0POZ00000WwQeJ2AV",
          "Event_Date__c": "2022-08-15",
          "Event_Description__c": "Clinical advice received from Analgesic Advisory Committee at meeting Thursday 5 May 2022.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">2022-05-05-Analgesics-Advisory-Committee-Record.pdf (pharmac.govt.nz)</a></p>",
          "Outcome__c": "High",
          "Formatted_Date__c": "Aug 2022",
          "Status_History__c": "a132P000000DzGRQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": "<p>5.1 The Committee (PTAC) reviewed the record of the Analgesic Advisory Committee held on 5 May 2022. PTAC noted the recommendations made by the Committee:</p><p><br></p><p>\u2022 that ketamine be listed in Section B of the Pharmaceutical Schedule for the treatment of palliative care patients in the community with intractable pain not adequately controlled with opioids with a high priority within the context of analgesic, anti-emetic and anaesthetic treatments, subject to endorsement [detailed in the full record]. </p><p><br></p><p>\u2022 that lidocaine 10% be listed in Section B and Section H of the Pharmaceutical Schedule for the treatment of terminally ill patients whose (mainly neuropathic) pain is not controlled, and the IV route is not appropriate with a high priority, within the context of analgesic, antiemetic, and anaesthetic treatments, subject to endorsement [detailed in the full record].</p><p><br></p><p>\u2022 that subcutaneous (SC) levetiracetam (inj 100 mg per ml, 5 ml vial) be listed in Section B of the Pharmaceutical Schedule with a medium priority, within the context of analgesic, antiemetic and anaesthetic treatments, subject to endorsement [detailed in the full record].</p><p><br></p><p>\u2022 that methylnaltrexone bromide for opioid induced constipation be listed with a medium priority within the context of analgesic, antiemetic and anaesthetic treatments subject to Special Authority criteria [detailed in the full record]. </p><p><br></p><p>5.2 Regarding item 10, Ketamine (community use) \u2013 Pain \u2013 palliative care patients with intractable pain not controlled with opioids: </p><p><br></p><p>\u2022 The Committee noted the Analgesic Advisory Committee had recommended ketamine be funded for the treatment of palliative care patients in the community with intractable pain not adequately controlled with opioids with a high priority. </p><p><br></p><p>\u2022 The Committee considered that currently hospitals can use ketamine for any indication, including palliative care, and therefore there could be inequities in primary care.</p><p><br></p><p>\u2022 The Committee considered that the experts on the Specialist Advisory Committee had on the ground experience with palliative care and acknowledged the high health need of palliative care patients and their wh\u0101nau. </p><p><br></p><p>\u2022 The Committee considered that there was a risk of ketamine misuse in the community setting and caution would be needed with regards to access criteria. </p><p><br></p><p>\u2022 The Committee considered some level 4 evidence (eg case reports or case series) and/or real-world data would be useful to assist with interpreting the benefit from ketamine in the palliative care setting. </p><p><br></p><p>\u2022 The Committee considered a randomised, double-blind, placebo-controlled trial by Hardy et al. (Hardy et al. J Clin Oncol. 2012;30:3611-7) that reported no benefit of ketamine over placebo. The Committee highlighted concerns that ketamine may do more harm than benefit in the palliative care setting due to psychomimetic adverse effects and that evidence to support positive health outcomes from treatment from ketamine was overshadowed by the adverse effect profile of the drug. The Committee recommended that a paper be bought back for PTAC to review the evidence in full.</p>",
          "fs": "<p>5.1 The Committee (PTAC) reviewed the record of the Analgesic Advisory Committee held on 5 May 2022. PTAC noted the recommendations made by the Committee:</p><p><br></p><p>\u2022 that ketamine be listed in Section B of the Pharmaceutical Schedule for the treatment of palliative care patients in the community with intractable pain not adequately controlled with opioids with a high priority within the context of analgesic, anti-emetic and anaesthetic treatments, subject to endorsement [detailed in the full record]. </p><p><br></p><p>\u2022 that lidocaine 10% be listed in Section B and Section H of the Pharmaceutical Schedule for the treatment of terminally ill patients whose (mainly neuropathic) pain is not controlled, and the IV route is not appropriate with a high priority, within the context of analgesic, antiemetic, and anaesthetic treatments, subject to endorsement [detailed in the full record].</p><p><br></p><p>\u2022 that subcutaneous (SC) levetiracetam (inj 100 mg per ml, 5 ml vial) be listed in Section B of the Pharmaceutical Schedule with a medium priority, within the context of analgesic, antiemetic and anaesthetic treatments, subject to endorsement [detailed in the full record].</p><p><br></p><p>\u2022 that methylnaltrexone bromide for opioid induced constipation be listed with a medium priority within the context of analgesic, antiemetic and anaesthetic treatments subject to Special Authority criteria [detailed in the full record]. </p><p><br></p><p>5.2 Regarding item 10, Ketamine (community use) \u2013 Pain \u2013 palliative care patients with intractable pain not controlled with opioids: </p><p><br></p><p>\u2022 The Committee noted the Analgesic Advisory Committee had recommended ketamine be funded for the treatment of palliative care patients in the community with intractable pain not adequately controlled with opioids with a high priority. </p><p><br></p><p>\u2022 The Committee considered that currently hospitals can use ketamine for any indication, including palliative care, and therefore there could be inequities in primary care.</p><p><br></p><p>\u2022 The Committee considered that the experts on the Specialist Advisory Committee had on the ground experience with palliative care and acknowledged the high health need of palliative care patients and their wh\u0101nau. </p><p><br></p><p>\u2022 The Committee considered that there was a risk of ketamine misuse in the community setting and caution would be needed with regards to access criteria. </p><p><br></p><p>\u2022 The Committee considered some level 4 evidence (eg case reports or case series) and/or real-world data would be useful to assist with interpreting the benefit from ketamine in the palliative care setting. </p><p><br></p><p>\u2022 The Committee considered a randomised, double-blind, placebo-controlled trial by Hardy et al. (Hardy et al. J Clin Oncol. 2012;30:3611-7) that reported no benefit of ketamine over placebo. The Committee highlighted concerns that ketamine may do more harm than benefit in the palliative care setting due to psychomimetic adverse effects and that evidence to support positive health outcomes from treatment from ketamine was overshadowed by the adverse effect profile of the drug. The Committee recommended that a paper be bought back for PTAC to review the evidence in full.</p>",
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "No Formal Recommendation",
          "fs": "No Formal Recommendation",
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/assets/2022-08-combined-PTAC-meeting-record.pdf\" target=\"_blank\">Meeting record</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/assets/2022-08-combined-PTAC-meeting-record.pdf\" target=\"_blank\">Meeting record</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2022",
          "fs": "Nov 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 18 August 2022.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 18 August 2022.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeK2AV"
          },
          "Id": "a0POZ00000WwQeK2AV",
          "Event_Date__c": "2022-11-30",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 18 August 2022.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/assets/2022-08-combined-PTAC-meeting-record.pdf\" target=\"_blank\">Meeting record</a></p>",
          "Outcome__c": "No Formal Recommendation",
          "Formatted_Date__c": "Nov 2022",
          "Published_Discussion__c": "<p>5.1 The Committee (PTAC) reviewed the record of the Analgesic Advisory Committee held on 5 May 2022. PTAC noted the recommendations made by the Committee:</p><p><br></p><p>\u2022 that ketamine be listed in Section B of the Pharmaceutical Schedule for the treatment of palliative care patients in the community with intractable pain not adequately controlled with opioids with a high priority within the context of analgesic, anti-emetic and anaesthetic treatments, subject to endorsement [detailed in the full record]. </p><p><br></p><p>\u2022 that lidocaine 10% be listed in Section B and Section H of the Pharmaceutical Schedule for the treatment of terminally ill patients whose (mainly neuropathic) pain is not controlled, and the IV route is not appropriate with a high priority, within the context of analgesic, antiemetic, and anaesthetic treatments, subject to endorsement [detailed in the full record].</p><p><br></p><p>\u2022 that subcutaneous (SC) levetiracetam (inj 100 mg per ml, 5 ml vial) be listed in Section B of the Pharmaceutical Schedule with a medium priority, within the context of analgesic, antiemetic and anaesthetic treatments, subject to endorsement [detailed in the full record].</p><p><br></p><p>\u2022 that methylnaltrexone bromide for opioid induced constipation be listed with a medium priority within the context of analgesic, antiemetic and anaesthetic treatments subject to Special Authority criteria [detailed in the full record]. </p><p><br></p><p>5.2 Regarding item 10, Ketamine (community use) \u2013 Pain \u2013 palliative care patients with intractable pain not controlled with opioids: </p><p><br></p><p>\u2022 The Committee noted the Analgesic Advisory Committee had recommended ketamine be funded for the treatment of palliative care patients in the community with intractable pain not adequately controlled with opioids with a high priority. </p><p><br></p><p>\u2022 The Committee considered that currently hospitals can use ketamine for any indication, including palliative care, and therefore there could be inequities in primary care.</p><p><br></p><p>\u2022 The Committee considered that the experts on the Specialist Advisory Committee had on the ground experience with palliative care and acknowledged the high health need of palliative care patients and their wh\u0101nau. </p><p><br></p><p>\u2022 The Committee considered that there was a risk of ketamine misuse in the community setting and caution would be needed with regards to access criteria. </p><p><br></p><p>\u2022 The Committee considered some level 4 evidence (eg case reports or case series) and/or real-world data would be useful to assist with interpreting the benefit from ketamine in the palliative care setting. </p><p><br></p><p>\u2022 The Committee considered a randomised, double-blind, placebo-controlled trial by Hardy et al. (Hardy et al. J Clin Oncol. 2012;30:3611-7) that reported no benefit of ketamine over placebo. The Committee highlighted concerns that ketamine may do more harm than benefit in the palliative care setting due to psychomimetic adverse effects and that evidence to support positive health outcomes from treatment from ketamine was overshadowed by the adverse effect profile of the drug. The Committee recommended that a paper be bought back for PTAC to review the evidence in full.</p>",
          "Status_History__c": "a132P000000EDDaQAO"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2022",
          "fs": "Dec 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeL2AV"
          },
          "Id": "a0POZ00000WwQeL2AV",
          "Event_Date__c": "2022-12-05",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Dec 2022",
          "Status_History__c": "a132P000000ED5YQAW"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2022",
          "fs": "Dec 2022",
          "change": null
        },
        "Event_Description": {
          "s": "Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 February 2023",
          "fs": "Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 February 2023",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeM2AV"
          },
          "Id": "a0POZ00000WwQeM2AV",
          "Event_Date__c": "2022-12-16",
          "Event_Description__c": "Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 February 2023",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Dec 2022",
          "Status_History__c": "a132P000000EDCzQAO"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee <strong>recommended</strong> that <span style=\"color: black;\">ketamine injection 100 mg per ml (2 ml vial) for community use in individuals receiving palliative care with intractable pain not adequately controlled with opioids </span>be listed in Section B of the Pharmaceutical Schedule with a <strong>low priority</strong>.</p><p><br></p><p class=\"ql-indent-1\"><strong style=\"font-size: 11px;\">KETAMINE</strong><span style=\"font-size: 11px;\"> \u2013 Subsidy by endorsement</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 11px;\">Subsidised only if endorsed, for use for a patient receiving palliative care who has intractable pain that is not managed adequately with current therapy for end-of-life care.</span></p><p class=\"ql-indent-1\"><br></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In making this recommendation, the Committee considered:</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of those with intractable pain receiving palliative care in a community setting, such as those in hospice or home-based care;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The health need of the wh\u0101nau caring for a person receiving palliative care experiencing intractable pain unresponsive to opioids;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The paucity of published evidence of benefit, and the published evidence of potential harm (Hardy et al <a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081\" target=\"_blank\">J Clin Oncol. 2012;30:3611-7</a>), balanced alongside the considerable clinical experience, of palliative medicine specialists and hospital-based acute pain services, that ketamine may provide a health benefit for those receiving palliative care with intractable pain;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The potential cost-savings to the health system, of funding ketamine in the community setting for this group of people; </p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The potential to reduce the number of people requiring hospital admission for management of intractable pain in palliative care;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it is important to ensure equitable access to treatment for those for whom hospital admission for administration of ketamine would not be practical;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That funding ketamine in the community setting for this group of individuals could provide more equitable palliative care treatment, as it would allow individuals to be treated in hospice and/or in their homes in their last days. </p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that due to the considerable safety considerations associated with ketamine use and administration, it should only be used for individuals receiving palliative care with intractable pain not adequately managed with other end-of-life treatments.\u00a0\u00a0</p>",
          "fs": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee <strong>recommended</strong> that <span style=\"color: black;\">ketamine injection 100 mg per ml (2 ml vial) for community use in individuals receiving palliative care with intractable pain not adequately controlled with opioids </span>be listed in Section B of the Pharmaceutical Schedule with a <strong>low priority</strong>.</p><p><br></p><p class=\"ql-indent-1\"><strong style=\"font-size: 11px;\">KETAMINE</strong><span style=\"font-size: 11px;\"> \u2013 Subsidy by endorsement</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 11px;\">Subsidised only if endorsed, for use for a patient receiving palliative care who has intractable pain that is not managed adequately with current therapy for end-of-life care.</span></p><p class=\"ql-indent-1\"><br></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In making this recommendation, the Committee considered:</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of those with intractable pain receiving palliative care in a community setting, such as those in hospice or home-based care;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The health need of the wh\u0101nau caring for a person receiving palliative care experiencing intractable pain unresponsive to opioids;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The paucity of published evidence of benefit, and the published evidence of potential harm (Hardy et al <a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081\" target=\"_blank\">J Clin Oncol. 2012;30:3611-7</a>), balanced alongside the considerable clinical experience, of palliative medicine specialists and hospital-based acute pain services, that ketamine may provide a health benefit for those receiving palliative care with intractable pain;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The potential cost-savings to the health system, of funding ketamine in the community setting for this group of people; </p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The potential to reduce the number of people requiring hospital admission for management of intractable pain in palliative care;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it is important to ensure equitable access to treatment for those for whom hospital admission for administration of ketamine would not be practical;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That funding ketamine in the community setting for this group of individuals could provide more equitable palliative care treatment, as it would allow individuals to be treated in hospice and/or in their homes in their last days. </p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that due to the considerable safety considerations associated with ketamine use and administration, it should only be used for individuals receiving palliative care with intractable pain not adequately managed with other end-of-life treatments.\u00a0\u00a0</p>",
          "change": null
        },
        "Published_Discussion": {
          "s": "<h2><strong style=\"font-size: 14px;\"><em>M\u0101ori impact</em></strong></h2><p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee discussed the impact of funding ketamine for palliative care in the community setting on M\u0101ori health areas of focus and M\u0101ori health outcomes. The Committee considered that funding ketamine in this setting may be beneficial for M\u0101ori, who may prefer to receive palliative care at home, supported by their wh\u0101nau rather than in a hospital setting.</p><h2><strong style=\"font-size: 14px;\"><em>Background</em></strong></h2><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the use of ketamine in the palliative care setting has been discussed extensively since 2009, with the Analgesic Specialist Advisory Committee most recently recommending it for funding in the community palliative care setting with a high priority (<a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">May 2022</a>). The Committee noted that it reviewed the records from the Analgesic Specialist Advisory Committee meeting in May 2022, and recommended that the item come back to PTAC to review the evidence in full.</p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that in 2012 it considered the evidence for ketamine burst therapy in the published paper by Hardy et al. (<a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081\" target=\"_blank\">J Clin Oncol. 2012;30:3611-7</a>), which reported no evidence of benefit for ketamine over placebo in pain management in patients with intractable pain unresponsive to opioids (record unpublished). The Committee also noted that Pharmac had and has received a number of Named Patient Pharmaceutical Assessment applications for the use of ketamine in the palliative setting, all of which were for continuous ketamine therapy, as opposed to burst therapy, and for when <span style=\"color: rgb(34, 34, 34);\">spinal anaesthesia was unsuitable or impractical</span>.</p><h2><strong style=\"font-size: 14px;\"><em>Health need</em></strong></h2><p>1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that the health needs of individuals receiving palliative care with intractable cancer pain have been well described previously, most recently in the record of the Analgesics Specialist Advisory Committee\u2019s <a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">May 2022</a> meeting. The Committee noted that the primary purpose of palliative care is to improve the quality of life of individuals towards the end of their life, and potentially also helping to support their family and wh\u0101nau during this time.</p><p>1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that ketamine, in various presentations, is currently funded in Section H of the Pharmaceutical Schedule without restriction. The Committee noted that ketamine is not listed in Section B of the Pharmaceutical Schedule and is therefore not funded for use in the community setting, which precludes access to those receiving hospice or home-based palliative care. The Committee considered that there consequently is a high health need for those receiving palliative care in the community with intractable pain that cannot be effectively managed with other treatments. People in this setting would need to be admitted to hospital to access ketamine infusions, which could be a barrier for some, especially people living rurally, those without transport options or for those who would prefer to receive treatment at home.</p><h2><strong style=\"font-size: 14px;\"><em>Health benefit</em></strong></h2><p>1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the use of ketamine in the palliative care setting is primarily driven by protocol and the recommendations by speciality palliative medicine/care groups, and that there is limited clinical evidence for the use of ketamine therapy in end-of-life care, despite there being evidence in treatment settings outside of palliative care for its use in seizure control and analgesia. The Committee noted that guidelines for the use of ketamine in palliative care state that it should only be initiated by a specialist, and occasionally by a general practitioner whilst the individual receiving care remains under the care of a palliative medicine specialist who can advise on appropriate dosing.</p><p>1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that adverse effects of ketamine treatment include upper gastrointestinal, hepatobiliary, urinary, and neuropsychiatric toxicity.</p><p>1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted the following evidence relating to the use of ketamine in palliative care:</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012;30:3611-7</a>: a dose-escalation, double-blind, randomised, placebo-controlled trial in which subcutaneous ketamine was administered as 3 to 5 day burst therapy in the management of cancer pain. The intention-to-treat sample comprised 185 patients (ketamine, 93; placebo, 92). Of these, 149 met the de\ufb01nition of completion. Seventy-four participants received study drug on all 5 days. The number of patients needed to treat for one additional patient to have a positive outcome from ketamine was 25 (95% CI, six to \u221e). The number needed to harm, because of toxicity-related withdrawal, was six (95% CI, four to 13). The authors concluded that ketamine does not have net clinical benefit when used as an adjunct to opioids and standard co-analgesics in the treatment of cancer pain.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://onlinelibrary.wiley.com/doi/10.1002/ejp.624\" target=\"_blank\">Marchetti et al. Eur J Pain. 2015;19:984-93</a>: a 5-year retrospective cohort study involving testing ketamine by intravenous in-hospital administration, then a conversion to an oral route, or oral treatment directly administered at home. Among 55 cases (51 patients, neuropathic pain 60%), the mean effective oral dose was 2 mg/kg. Ketamine was effective in 24 patients (44%, mean pain reduction 67 \u00b1 17%), partially effective in 20% (mean pain reduction 30 \u00b1 11%).</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://pubs.asahq.org/anesthesiology/article-lookup/doi/10.1097/ALN.0000000000003345\" target=\"_blank\">Pickering et al. Anesthesiology. 2020;133:154-64</a>: a randomised, double-blind, crossover, placebo-controlled study in 20 patients with refractory neuropathic pain who were ketamine-na\u00efve. Patients received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulphate (3 g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion, which was not significantly different between the three groups (N = 20) over 35 days (mean area under the curve = 185 \u00b1 100, 196 \u00b1 92, and 187 \u00b1 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively, P = 0.296)</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://pubmed.ncbi.nlm.nih.gov/22335487/\" target=\"_blank\">Salas et al. J Palliat Med. 2012;15:287-93</a>: a randomised, double-blind, placebo-controlled trial designed to assess efficacy of continuous intravenous infusion of ketamine in patients suffering from cancer pain refractory to opiates who had been admitted to palliative care units. Secondary objectives were to assess patients\u2019 satisfaction with and tolerance of ketamine. Twenty patients were analysed (11 received ketamine and 9 received placebo). Self-reported pain did not differ between the two groups, as the symptoms continued to evolve during the study period. The tolerance for ketamine was reported as satisfactory.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://journals.lww.com/co-supportiveandpalliativecare/Abstract/2017/06000/Ketamine_for_cancer_pain__what_is_the_evidence_.4.aspx\" target=\"_blank\">Jonkman et al. Curr Opin Support Palliat Care. 2017;11:88-92</a>: a review of the benefit of ketamine in the treatment of terminal cancer pain that is refractory to opioid treatment and/or complicated by neuropathy. Authors reported that while randomised controlled trials consistently show lack of clinical efficacy of ketamine in treating cancer pain, a large number of open-label studies and case series show benefit.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://www.liebertpub.com/doi/epub/10.1089/jpm.2018.0627\" target=\"_blank\">Goldman et al. J Palliat Med. 2019;22:1154-61</a>: a review examining the efficacy of ketamine for the treatment of depression and physical pain in palliative care patients. Ketamine\u2019s effect on treating physical pain was mixed with the largest and most recent randomised controlled trials suggesting no significant analgesic effect.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152774/\" target=\"_blank\">Benini et al. Drugs Context. 2021;10:2021-2-5</a>: a review analysing the use of ketamine in children and the potential extension of its applications in paediatric palliative care (PPC). The authors reported that the use of ketamine in PPC should be more widely considered due to its overall favourable safety profile and efficacy, which are supported by an increasing number of studies, although in settings different from PPC and of mixed quality.</p><p>1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that, overall, the strength and quality of evidence was weak. The Committee considered that there is evidence of poor effectiveness for the use of ketamine in this setting, and that the studies were very heterogeneous (palliative care versus chronic pain, varying pain types, ketamine was occasionally supplemental to other therapies, variable duration of treatment and of treatment benefit, variable dose and administration route) and that the studies had relatively few participants or were uncontrolled non-comparative individual case reports. The Committee also noted that there are also often various other conditions that may also be present when an individual has a terminal illness, such as anxiety and depression. The Committee noted that adverse events commonly reported associated with ketamine were somnolescence (sleepiness), psychotomimetic symptoms, and cystitis.\u00a0</p><p>1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee also noted a review examining the efficacy of ketamine for the treatment of depression and physical pain in palliative care patients (<a href=\"https://pubmed.ncbi.nlm.nih.gov/31090477/\" target=\"_blank\">Goldman et al. J Palliat Med. 2019;22:1154-61</a>). The Committee noted that the evidence for the efficacy of ketamine in treating physical pain was mixed, and all studies included in the Goldman et al. review reported antidepressant effects of ketamine in this population. The Committee considered the quality-of-life gain from mood improvements during end-of-life care to be beneficial but noted that there currently is no evidence to support a benefit with longer-term ketamine treatment.</p><p>1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered it unlikely that better quality data would be forthcoming in this space, as palliative care physicians are already widely using ketamine in palliative care, and it is difficult to conduct randomised trials with individuals who are receiving end-of-life care.</p><p>1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee also considered that individuals who respond favourably to ketamine while in hospital may benefit from ongoing therapy outside of hospital (ie via hospice or home-based palliative care) for a short duration of time.</p><p>1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that ketamine has an effect characterised by a steep concentration-response curve, with high variability between individuals. The Committee noted that treatment with ketamine can quickly escalate from analgesia to anaesthesia. The Committee considered that it was important to not cause distress to individuals, or their family/wh\u0101nau, at end of life, and that risk mitigation with regard to adverse events and diversion would need to be carefully considered if ketamine were to be funded in the community setting.</p><p>1.14.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that, on balance, the potential health benefits of ketamine for intractable pain in people receiving palliative care who have no funded alternatives outweigh the potential for adverse effects from treatment with ketamine. The Committee also considered that ketamine treatment would be ceased quickly if the individual receiving treatment did not receive obvious clinical benefits.</p><h2><strong style=\"font-size: 14px;\"><em>Suitability</em></strong></h2><p>1.15.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that if ketamine were funded in community for use in palliative care it would be administered via an infusion, and that this would need to be supported by health care professionals as those receiving treatment or their wh\u0101nau or caregivers would not be able to administer the medication. The Committee considered that people receiving palliative care in the community were most likely to already be receiving support from health care professionals regarding the administration of their other medications (eg opioid infusions/subcutaneous injections) and care.</p><p>1.16.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the following formulations of ketamine are listed in Section H of the Pharmaceutical Schedule: 1 mg per ml for injection (100 ml bag), 10 mg per ml for injection (10 ml syringe), and 100 mg per ml (2 ml vial).\u00a0Members considered that the 100 mg per ml (2 ml vial) presentation would be most appropriate for use in the community as this would allow administration via a syringe driver at various concentrations.</p><h2><strong style=\"font-size: 14px;\"><em>Cost and savings</em></strong></h2><p>1.17.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the estimated number of individuals receiving ketamine in the palliative care setting ranges widely and that the estimates by Pharmac staff were reasonable. The Committee noted that the number of people who may be eligible could therefore be as low as 75 per annum and as high as 600-700 annually. The Committee considered that ketamine being offered in the palliative care setting in the community may reduce the burden on hospital inpatient resources, as these individuals would not then require admission to hospital for the management of their pain.</p><p>1.18.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that any interventions, pharmacological or related to health care resource, used to manage any adverse effects of ketamine would likely be minimal given the treatment would be used in the end-of-life care setting.</p><h2><strong style=\"font-size: 14px;\"><em>Summary for assessment</em></strong></h2><p>1.19.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ketamine if it were to be funded in New Zealand for the management of intractable pain in palliative care in the community. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee\u2019s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. <span style=\"color: black;\">\u00a0</span></p><p><img src=\"/apptracker/servlet/rtaImage?eid=a0POZ00000WwQeN&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002mkh7\" alt=\"image.png\"></img></p>",
          "fs": "<h2><strong style=\"font-size: 14px;\"><em>M\u0101ori impact</em></strong></h2><p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee discussed the impact of funding ketamine for palliative care in the community setting on M\u0101ori health areas of focus and M\u0101ori health outcomes. The Committee considered that funding ketamine in this setting may be beneficial for M\u0101ori, who may prefer to receive palliative care at home, supported by their wh\u0101nau rather than in a hospital setting.</p><h2><strong style=\"font-size: 14px;\"><em>Background</em></strong></h2><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the use of ketamine in the palliative care setting has been discussed extensively since 2009, with the Analgesic Specialist Advisory Committee most recently recommending it for funding in the community palliative care setting with a high priority (<a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">May 2022</a>). The Committee noted that it reviewed the records from the Analgesic Specialist Advisory Committee meeting in May 2022, and recommended that the item come back to PTAC to review the evidence in full.</p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that in 2012 it considered the evidence for ketamine burst therapy in the published paper by Hardy et al. (<a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081\" target=\"_blank\">J Clin Oncol. 2012;30:3611-7</a>), which reported no evidence of benefit for ketamine over placebo in pain management in patients with intractable pain unresponsive to opioids (record unpublished). The Committee also noted that Pharmac had and has received a number of Named Patient Pharmaceutical Assessment applications for the use of ketamine in the palliative setting, all of which were for continuous ketamine therapy, as opposed to burst therapy, and for when <span style=\"color: rgb(34, 34, 34);\">spinal anaesthesia was unsuitable or impractical</span>.</p><h2><strong style=\"font-size: 14px;\"><em>Health need</em></strong></h2><p>1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that the health needs of individuals receiving palliative care with intractable cancer pain have been well described previously, most recently in the record of the Analgesics Specialist Advisory Committee\u2019s <a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">May 2022</a> meeting. The Committee noted that the primary purpose of palliative care is to improve the quality of life of individuals towards the end of their life, and potentially also helping to support their family and wh\u0101nau during this time.</p><p>1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that ketamine, in various presentations, is currently funded in Section H of the Pharmaceutical Schedule without restriction. The Committee noted that ketamine is not listed in Section B of the Pharmaceutical Schedule and is therefore not funded for use in the community setting, which precludes access to those receiving hospice or home-based palliative care. The Committee considered that there consequently is a high health need for those receiving palliative care in the community with intractable pain that cannot be effectively managed with other treatments. People in this setting would need to be admitted to hospital to access ketamine infusions, which could be a barrier for some, especially people living rurally, those without transport options or for those who would prefer to receive treatment at home.</p><h2><strong style=\"font-size: 14px;\"><em>Health benefit</em></strong></h2><p>1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the use of ketamine in the palliative care setting is primarily driven by protocol and the recommendations by speciality palliative medicine/care groups, and that there is limited clinical evidence for the use of ketamine therapy in end-of-life care, despite there being evidence in treatment settings outside of palliative care for its use in seizure control and analgesia. The Committee noted that guidelines for the use of ketamine in palliative care state that it should only be initiated by a specialist, and occasionally by a general practitioner whilst the individual receiving care remains under the care of a palliative medicine specialist who can advise on appropriate dosing.</p><p>1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that adverse effects of ketamine treatment include upper gastrointestinal, hepatobiliary, urinary, and neuropsychiatric toxicity.</p><p>1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted the following evidence relating to the use of ketamine in palliative care:</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012;30:3611-7</a>: a dose-escalation, double-blind, randomised, placebo-controlled trial in which subcutaneous ketamine was administered as 3 to 5 day burst therapy in the management of cancer pain. The intention-to-treat sample comprised 185 patients (ketamine, 93; placebo, 92). Of these, 149 met the de\ufb01nition of completion. Seventy-four participants received study drug on all 5 days. The number of patients needed to treat for one additional patient to have a positive outcome from ketamine was 25 (95% CI, six to \u221e). The number needed to harm, because of toxicity-related withdrawal, was six (95% CI, four to 13). The authors concluded that ketamine does not have net clinical benefit when used as an adjunct to opioids and standard co-analgesics in the treatment of cancer pain.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://onlinelibrary.wiley.com/doi/10.1002/ejp.624\" target=\"_blank\">Marchetti et al. Eur J Pain. 2015;19:984-93</a>: a 5-year retrospective cohort study involving testing ketamine by intravenous in-hospital administration, then a conversion to an oral route, or oral treatment directly administered at home. Among 55 cases (51 patients, neuropathic pain 60%), the mean effective oral dose was 2 mg/kg. Ketamine was effective in 24 patients (44%, mean pain reduction 67 \u00b1 17%), partially effective in 20% (mean pain reduction 30 \u00b1 11%).</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://pubs.asahq.org/anesthesiology/article-lookup/doi/10.1097/ALN.0000000000003345\" target=\"_blank\">Pickering et al. Anesthesiology. 2020;133:154-64</a>: a randomised, double-blind, crossover, placebo-controlled study in 20 patients with refractory neuropathic pain who were ketamine-na\u00efve. Patients received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulphate (3 g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion, which was not significantly different between the three groups (N = 20) over 35 days (mean area under the curve = 185 \u00b1 100, 196 \u00b1 92, and 187 \u00b1 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively, P = 0.296)</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://pubmed.ncbi.nlm.nih.gov/22335487/\" target=\"_blank\">Salas et al. J Palliat Med. 2012;15:287-93</a>: a randomised, double-blind, placebo-controlled trial designed to assess efficacy of continuous intravenous infusion of ketamine in patients suffering from cancer pain refractory to opiates who had been admitted to palliative care units. Secondary objectives were to assess patients\u2019 satisfaction with and tolerance of ketamine. Twenty patients were analysed (11 received ketamine and 9 received placebo). Self-reported pain did not differ between the two groups, as the symptoms continued to evolve during the study period. The tolerance for ketamine was reported as satisfactory.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://journals.lww.com/co-supportiveandpalliativecare/Abstract/2017/06000/Ketamine_for_cancer_pain__what_is_the_evidence_.4.aspx\" target=\"_blank\">Jonkman et al. Curr Opin Support Palliat Care. 2017;11:88-92</a>: a review of the benefit of ketamine in the treatment of terminal cancer pain that is refractory to opioid treatment and/or complicated by neuropathy. Authors reported that while randomised controlled trials consistently show lack of clinical efficacy of ketamine in treating cancer pain, a large number of open-label studies and case series show benefit.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://www.liebertpub.com/doi/epub/10.1089/jpm.2018.0627\" target=\"_blank\">Goldman et al. J Palliat Med. 2019;22:1154-61</a>: a review examining the efficacy of ketamine for the treatment of depression and physical pain in palliative care patients. Ketamine\u2019s effect on treating physical pain was mixed with the largest and most recent randomised controlled trials suggesting no significant analgesic effect.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152774/\" target=\"_blank\">Benini et al. Drugs Context. 2021;10:2021-2-5</a>: a review analysing the use of ketamine in children and the potential extension of its applications in paediatric palliative care (PPC). The authors reported that the use of ketamine in PPC should be more widely considered due to its overall favourable safety profile and efficacy, which are supported by an increasing number of studies, although in settings different from PPC and of mixed quality.</p><p>1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that, overall, the strength and quality of evidence was weak. The Committee considered that there is evidence of poor effectiveness for the use of ketamine in this setting, and that the studies were very heterogeneous (palliative care versus chronic pain, varying pain types, ketamine was occasionally supplemental to other therapies, variable duration of treatment and of treatment benefit, variable dose and administration route) and that the studies had relatively few participants or were uncontrolled non-comparative individual case reports. The Committee also noted that there are also often various other conditions that may also be present when an individual has a terminal illness, such as anxiety and depression. The Committee noted that adverse events commonly reported associated with ketamine were somnolescence (sleepiness), psychotomimetic symptoms, and cystitis.\u00a0</p><p>1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee also noted a review examining the efficacy of ketamine for the treatment of depression and physical pain in palliative care patients (<a href=\"https://pubmed.ncbi.nlm.nih.gov/31090477/\" target=\"_blank\">Goldman et al. J Palliat Med. 2019;22:1154-61</a>). The Committee noted that the evidence for the efficacy of ketamine in treating physical pain was mixed, and all studies included in the Goldman et al. review reported antidepressant effects of ketamine in this population. The Committee considered the quality-of-life gain from mood improvements during end-of-life care to be beneficial but noted that there currently is no evidence to support a benefit with longer-term ketamine treatment.</p><p>1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered it unlikely that better quality data would be forthcoming in this space, as palliative care physicians are already widely using ketamine in palliative care, and it is difficult to conduct randomised trials with individuals who are receiving end-of-life care.</p><p>1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee also considered that individuals who respond favourably to ketamine while in hospital may benefit from ongoing therapy outside of hospital (ie via hospice or home-based palliative care) for a short duration of time.</p><p>1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that ketamine has an effect characterised by a steep concentration-response curve, with high variability between individuals. The Committee noted that treatment with ketamine can quickly escalate from analgesia to anaesthesia. The Committee considered that it was important to not cause distress to individuals, or their family/wh\u0101nau, at end of life, and that risk mitigation with regard to adverse events and diversion would need to be carefully considered if ketamine were to be funded in the community setting.</p><p>1.14.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that, on balance, the potential health benefits of ketamine for intractable pain in people receiving palliative care who have no funded alternatives outweigh the potential for adverse effects from treatment with ketamine. The Committee also considered that ketamine treatment would be ceased quickly if the individual receiving treatment did not receive obvious clinical benefits.</p><h2><strong style=\"font-size: 14px;\"><em>Suitability</em></strong></h2><p>1.15.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that if ketamine were funded in community for use in palliative care it would be administered via an infusion, and that this would need to be supported by health care professionals as those receiving treatment or their wh\u0101nau or caregivers would not be able to administer the medication. The Committee considered that people receiving palliative care in the community were most likely to already be receiving support from health care professionals regarding the administration of their other medications (eg opioid infusions/subcutaneous injections) and care.</p><p>1.16.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the following formulations of ketamine are listed in Section H of the Pharmaceutical Schedule: 1 mg per ml for injection (100 ml bag), 10 mg per ml for injection (10 ml syringe), and 100 mg per ml (2 ml vial).\u00a0Members considered that the 100 mg per ml (2 ml vial) presentation would be most appropriate for use in the community as this would allow administration via a syringe driver at various concentrations.</p><h2><strong style=\"font-size: 14px;\"><em>Cost and savings</em></strong></h2><p>1.17.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the estimated number of individuals receiving ketamine in the palliative care setting ranges widely and that the estimates by Pharmac staff were reasonable. The Committee noted that the number of people who may be eligible could therefore be as low as 75 per annum and as high as 600-700 annually. The Committee considered that ketamine being offered in the palliative care setting in the community may reduce the burden on hospital inpatient resources, as these individuals would not then require admission to hospital for the management of their pain.</p><p>1.18.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that any interventions, pharmacological or related to health care resource, used to manage any adverse effects of ketamine would likely be minimal given the treatment would be used in the end-of-life care setting.</p><h2><strong style=\"font-size: 14px;\"><em>Summary for assessment</em></strong></h2><p>1.19.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ketamine if it were to be funded in New Zealand for the management of intractable pain in palliative care in the community. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee\u2019s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. <span style=\"color: black;\">\u00a0</span></p><p><img src=\"/apptracker/servlet/rtaImage?eid=a0POZ00000WwQeN&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002mkh7\" alt=\"image.png\"></img></p>",
          "change": null
        },
        "Published_Application": {
          "s": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee reviewed the application for ketamine for community use in individuals receiving palliative care with intractable pain not adequately controlled with opioids.</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that, at its August 2022 meeting, PTAC requested this application be brought to the Committee for a full review of available evidence, following review of the meeting record from the August 2022 Analgesic Specialist Advisory Committee. </p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee took into account, where applicable, Pharmac\u2019s relevant decision-making framework when considering this agenda item.\u00a0</p>",
          "fs": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee reviewed the application for ketamine for community use in individuals receiving palliative care with intractable pain not adequately controlled with opioids.</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that, at its August 2022 meeting, PTAC requested this application be brought to the Committee for a full review of available evidence, following review of the meeting record from the August 2022 Analgesic Specialist Advisory Committee. </p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee took into account, where applicable, Pharmac\u2019s relevant decision-making framework when considering this agenda item.\u00a0</p>",
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Low",
          "fs": "Low",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2023",
          "fs": "Jun 2023",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 February 2023.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 February 2023.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeN2AV"
          },
          "Id": "a0POZ00000WwQeN2AV",
          "Event_Date__c": "2023-06-26",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 February 2023.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "Low",
          "Formatted_Date__c": "Jun 2023",
          "Published_Recommendation__c": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee <strong>recommended</strong> that <span style=\"color: black;\">ketamine injection 100 mg per ml (2 ml vial) for community use in individuals receiving palliative care with intractable pain not adequately controlled with opioids </span>be listed in Section B of the Pharmaceutical Schedule with a <strong>low priority</strong>.</p><p><br></p><p class=\"ql-indent-1\"><strong style=\"font-size: 11px;\">KETAMINE</strong><span style=\"font-size: 11px;\"> \u2013 Subsidy by endorsement</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 11px;\">Subsidised only if endorsed, for use for a patient receiving palliative care who has intractable pain that is not managed adequately with current therapy for end-of-life care.</span></p><p class=\"ql-indent-1\"><br></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In making this recommendation, the Committee considered:</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of those with intractable pain receiving palliative care in a community setting, such as those in hospice or home-based care;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The health need of the wh\u0101nau caring for a person receiving palliative care experiencing intractable pain unresponsive to opioids;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The paucity of published evidence of benefit, and the published evidence of potential harm (Hardy et al <a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081\" target=\"_blank\">J Clin Oncol. 2012;30:3611-7</a>), balanced alongside the considerable clinical experience, of palliative medicine specialists and hospital-based acute pain services, that ketamine may provide a health benefit for those receiving palliative care with intractable pain;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The potential cost-savings to the health system, of funding ketamine in the community setting for this group of people; </p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The potential to reduce the number of people requiring hospital admission for management of intractable pain in palliative care;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it is important to ensure equitable access to treatment for those for whom hospital admission for administration of ketamine would not be practical;</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That funding ketamine in the community setting for this group of individuals could provide more equitable palliative care treatment, as it would allow individuals to be treated in hospice and/or in their homes in their last days. </p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that due to the considerable safety considerations associated with ketamine use and administration, it should only be used for individuals receiving palliative care with intractable pain not adequately managed with other end-of-life treatments.\u00a0\u00a0</p>",
          "Published_Application__c": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee reviewed the application for ketamine for community use in individuals receiving palliative care with intractable pain not adequately controlled with opioids.</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that, at its August 2022 meeting, PTAC requested this application be brought to the Committee for a full review of available evidence, following review of the meeting record from the August 2022 Analgesic Specialist Advisory Committee. </p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee took into account, where applicable, Pharmac\u2019s relevant decision-making framework when considering this agenda item.\u00a0</p>",
          "Published_Discussion__c": "<h2><strong style=\"font-size: 14px;\"><em>M\u0101ori impact</em></strong></h2><p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee discussed the impact of funding ketamine for palliative care in the community setting on M\u0101ori health areas of focus and M\u0101ori health outcomes. The Committee considered that funding ketamine in this setting may be beneficial for M\u0101ori, who may prefer to receive palliative care at home, supported by their wh\u0101nau rather than in a hospital setting.</p><h2><strong style=\"font-size: 14px;\"><em>Background</em></strong></h2><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the use of ketamine in the palliative care setting has been discussed extensively since 2009, with the Analgesic Specialist Advisory Committee most recently recommending it for funding in the community palliative care setting with a high priority (<a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">May 2022</a>). The Committee noted that it reviewed the records from the Analgesic Specialist Advisory Committee meeting in May 2022, and recommended that the item come back to PTAC to review the evidence in full.</p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that in 2012 it considered the evidence for ketamine burst therapy in the published paper by Hardy et al. (<a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081\" target=\"_blank\">J Clin Oncol. 2012;30:3611-7</a>), which reported no evidence of benefit for ketamine over placebo in pain management in patients with intractable pain unresponsive to opioids (record unpublished). The Committee also noted that Pharmac had and has received a number of Named Patient Pharmaceutical Assessment applications for the use of ketamine in the palliative setting, all of which were for continuous ketamine therapy, as opposed to burst therapy, and for when <span style=\"color: rgb(34, 34, 34);\">spinal anaesthesia was unsuitable or impractical</span>.</p><h2><strong style=\"font-size: 14px;\"><em>Health need</em></strong></h2><p>1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that the health needs of individuals receiving palliative care with intractable cancer pain have been well described previously, most recently in the record of the Analgesics Specialist Advisory Committee\u2019s <a href=\"https://pharmac.govt.nz/assets/2022-05-05-Analgesics-Advisory-Committee-Record.pdf\" target=\"_blank\">May 2022</a> meeting. The Committee noted that the primary purpose of palliative care is to improve the quality of life of individuals towards the end of their life, and potentially also helping to support their family and wh\u0101nau during this time.</p><p>1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that ketamine, in various presentations, is currently funded in Section H of the Pharmaceutical Schedule without restriction. The Committee noted that ketamine is not listed in Section B of the Pharmaceutical Schedule and is therefore not funded for use in the community setting, which precludes access to those receiving hospice or home-based palliative care. The Committee considered that there consequently is a high health need for those receiving palliative care in the community with intractable pain that cannot be effectively managed with other treatments. People in this setting would need to be admitted to hospital to access ketamine infusions, which could be a barrier for some, especially people living rurally, those without transport options or for those who would prefer to receive treatment at home.</p><h2><strong style=\"font-size: 14px;\"><em>Health benefit</em></strong></h2><p>1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the use of ketamine in the palliative care setting is primarily driven by protocol and the recommendations by speciality palliative medicine/care groups, and that there is limited clinical evidence for the use of ketamine therapy in end-of-life care, despite there being evidence in treatment settings outside of palliative care for its use in seizure control and analgesia. The Committee noted that guidelines for the use of ketamine in palliative care state that it should only be initiated by a specialist, and occasionally by a general practitioner whilst the individual receiving care remains under the care of a palliative medicine specialist who can advise on appropriate dosing.</p><p>1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that adverse effects of ketamine treatment include upper gastrointestinal, hepatobiliary, urinary, and neuropsychiatric toxicity.</p><p>1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted the following evidence relating to the use of ketamine in palliative care:</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://ascopubs.org/doi/10.1200/JCO.2012.42.1081?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" target=\"_blank\">Hardy et al. J Clin Oncol. 2012;30:3611-7</a>: a dose-escalation, double-blind, randomised, placebo-controlled trial in which subcutaneous ketamine was administered as 3 to 5 day burst therapy in the management of cancer pain. The intention-to-treat sample comprised 185 patients (ketamine, 93; placebo, 92). Of these, 149 met the de\ufb01nition of completion. Seventy-four participants received study drug on all 5 days. The number of patients needed to treat for one additional patient to have a positive outcome from ketamine was 25 (95% CI, six to \u221e). The number needed to harm, because of toxicity-related withdrawal, was six (95% CI, four to 13). The authors concluded that ketamine does not have net clinical benefit when used as an adjunct to opioids and standard co-analgesics in the treatment of cancer pain.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://onlinelibrary.wiley.com/doi/10.1002/ejp.624\" target=\"_blank\">Marchetti et al. Eur J Pain. 2015;19:984-93</a>: a 5-year retrospective cohort study involving testing ketamine by intravenous in-hospital administration, then a conversion to an oral route, or oral treatment directly administered at home. Among 55 cases (51 patients, neuropathic pain 60%), the mean effective oral dose was 2 mg/kg. Ketamine was effective in 24 patients (44%, mean pain reduction 67 \u00b1 17%), partially effective in 20% (mean pain reduction 30 \u00b1 11%).</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://pubs.asahq.org/anesthesiology/article-lookup/doi/10.1097/ALN.0000000000003345\" target=\"_blank\">Pickering et al. Anesthesiology. 2020;133:154-64</a>: a randomised, double-blind, crossover, placebo-controlled study in 20 patients with refractory neuropathic pain who were ketamine-na\u00efve. Patients received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulphate (3 g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion, which was not significantly different between the three groups (N = 20) over 35 days (mean area under the curve = 185 \u00b1 100, 196 \u00b1 92, and 187 \u00b1 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively, P = 0.296)</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://pubmed.ncbi.nlm.nih.gov/22335487/\" target=\"_blank\">Salas et al. J Palliat Med. 2012;15:287-93</a>: a randomised, double-blind, placebo-controlled trial designed to assess efficacy of continuous intravenous infusion of ketamine in patients suffering from cancer pain refractory to opiates who had been admitted to palliative care units. Secondary objectives were to assess patients\u2019 satisfaction with and tolerance of ketamine. Twenty patients were analysed (11 received ketamine and 9 received placebo). Self-reported pain did not differ between the two groups, as the symptoms continued to evolve during the study period. The tolerance for ketamine was reported as satisfactory.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://journals.lww.com/co-supportiveandpalliativecare/Abstract/2017/06000/Ketamine_for_cancer_pain__what_is_the_evidence_.4.aspx\" target=\"_blank\">Jonkman et al. Curr Opin Support Palliat Care. 2017;11:88-92</a>: a review of the benefit of ketamine in the treatment of terminal cancer pain that is refractory to opioid treatment and/or complicated by neuropathy. Authors reported that while randomised controlled trials consistently show lack of clinical efficacy of ketamine in treating cancer pain, a large number of open-label studies and case series show benefit.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://www.liebertpub.com/doi/epub/10.1089/jpm.2018.0627\" target=\"_blank\">Goldman et al. J Palliat Med. 2019;22:1154-61</a>: a review examining the efficacy of ketamine for the treatment of depression and physical pain in palliative care patients. Ketamine\u2019s effect on treating physical pain was mixed with the largest and most recent randomised controlled trials suggesting no significant analgesic effect.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152774/\" target=\"_blank\">Benini et al. Drugs Context. 2021;10:2021-2-5</a>: a review analysing the use of ketamine in children and the potential extension of its applications in paediatric palliative care (PPC). The authors reported that the use of ketamine in PPC should be more widely considered due to its overall favourable safety profile and efficacy, which are supported by an increasing number of studies, although in settings different from PPC and of mixed quality.</p><p>1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that, overall, the strength and quality of evidence was weak. The Committee considered that there is evidence of poor effectiveness for the use of ketamine in this setting, and that the studies were very heterogeneous (palliative care versus chronic pain, varying pain types, ketamine was occasionally supplemental to other therapies, variable duration of treatment and of treatment benefit, variable dose and administration route) and that the studies had relatively few participants or were uncontrolled non-comparative individual case reports. The Committee also noted that there are also often various other conditions that may also be present when an individual has a terminal illness, such as anxiety and depression. The Committee noted that adverse events commonly reported associated with ketamine were somnolescence (sleepiness), psychotomimetic symptoms, and cystitis.\u00a0</p><p>1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee also noted a review examining the efficacy of ketamine for the treatment of depression and physical pain in palliative care patients (<a href=\"https://pubmed.ncbi.nlm.nih.gov/31090477/\" target=\"_blank\">Goldman et al. J Palliat Med. 2019;22:1154-61</a>). The Committee noted that the evidence for the efficacy of ketamine in treating physical pain was mixed, and all studies included in the Goldman et al. review reported antidepressant effects of ketamine in this population. The Committee considered the quality-of-life gain from mood improvements during end-of-life care to be beneficial but noted that there currently is no evidence to support a benefit with longer-term ketamine treatment.</p><p>1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered it unlikely that better quality data would be forthcoming in this space, as palliative care physicians are already widely using ketamine in palliative care, and it is difficult to conduct randomised trials with individuals who are receiving end-of-life care.</p><p>1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee also considered that individuals who respond favourably to ketamine while in hospital may benefit from ongoing therapy outside of hospital (ie via hospice or home-based palliative care) for a short duration of time.</p><p>1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that ketamine has an effect characterised by a steep concentration-response curve, with high variability between individuals. The Committee noted that treatment with ketamine can quickly escalate from analgesia to anaesthesia. The Committee considered that it was important to not cause distress to individuals, or their family/wh\u0101nau, at end of life, and that risk mitigation with regard to adverse events and diversion would need to be carefully considered if ketamine were to be funded in the community setting.</p><p>1.14.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that, on balance, the potential health benefits of ketamine for intractable pain in people receiving palliative care who have no funded alternatives outweigh the potential for adverse effects from treatment with ketamine. The Committee also considered that ketamine treatment would be ceased quickly if the individual receiving treatment did not receive obvious clinical benefits.</p><h2><strong style=\"font-size: 14px;\"><em>Suitability</em></strong></h2><p>1.15.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that if ketamine were funded in community for use in palliative care it would be administered via an infusion, and that this would need to be supported by health care professionals as those receiving treatment or their wh\u0101nau or caregivers would not be able to administer the medication. The Committee considered that people receiving palliative care in the community were most likely to already be receiving support from health care professionals regarding the administration of their other medications (eg opioid infusions/subcutaneous injections) and care.</p><p>1.16.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the following formulations of ketamine are listed in Section H of the Pharmaceutical Schedule: 1 mg per ml for injection (100 ml bag), 10 mg per ml for injection (10 ml syringe), and 100 mg per ml (2 ml vial).\u00a0Members considered that the 100 mg per ml (2 ml vial) presentation would be most appropriate for use in the community as this would allow administration via a syringe driver at various concentrations.</p><h2><strong style=\"font-size: 14px;\"><em>Cost and savings</em></strong></h2><p>1.17.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that the estimated number of individuals receiving ketamine in the palliative care setting ranges widely and that the estimates by Pharmac staff were reasonable. The Committee noted that the number of people who may be eligible could therefore be as low as 75 per annum and as high as 600-700 annually. The Committee considered that ketamine being offered in the palliative care setting in the community may reduce the burden on hospital inpatient resources, as these individuals would not then require admission to hospital for the management of their pain.</p><p>1.18.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that any interventions, pharmacological or related to health care resource, used to manage any adverse effects of ketamine would likely be minimal given the treatment would be used in the end-of-life care setting.</p><h2><strong style=\"font-size: 14px;\"><em>Summary for assessment</em></strong></h2><p>1.19.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ketamine if it were to be funded in New Zealand for the management of intractable pain in palliative care in the community. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee\u2019s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. <span style=\"color: black;\">\u00a0</span></p><p><img src=\"/apptracker/servlet/rtaImage?eid=a0POZ00000WwQeN&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002mkh7\" alt=\"image.png\"></img></p>",
          "Status_History__c": "a132P000000Egl4QAC"
        },
        "change": null
      }
    ],
    "dateString": "Mar 2009",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2009",
          "fs": "May 2009",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe52AF"
          },
          "Id": "a0POZ00000WwQe52AF",
          "Event_Date__c": "2009-05-01",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "May 2009",
          "Status_History__c": "a132P000000ApPvQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Mar 2020",
          "fs": "Mar 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeG2AV"
          },
          "Id": "a0POZ00000WwQeG2AV",
          "Event_Date__c": "2020-03-03",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Mar 2020",
          "Status_History__c": "a132P000000CvtAQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2023",
          "fs": "Jun 2023",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeO2AV"
          },
          "Id": "a0POZ00000WwQeO2AV",
          "Event_Date__c": "2023-06-27",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Jun 2023",
          "Status_History__c": "a13OZ000001dzeBYAQ"
        },
        "change": null
      }
    ],
    "dateString": "May 2009",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2009",
          "fs": "May 2009",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQe72AF"
          },
          "Id": "a0POZ00000WwQe72AF",
          "Event_Date__c": "2009-05-22",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "May 2009",
          "Status_History__c": "a132P000000ApR3QAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2013",
          "fs": "Nov 2013",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeC2AV"
          },
          "Id": "a0POZ00000WwQeC2AV",
          "Event_Date__c": "2013-11-05",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Nov 2013",
          "Status_History__c": "a132P000000AqWcQAK"
        },
        "change": null
      }
    ],
    "dateString": "May 2009",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2026-11-improving-access-to-treatments-in-the-community-for-trauma-and-medical-emergencies-and-ketamine-for-palliative-care\" target=\"_blank\">Consultation notification</a></p>",
          "fs": "<p><a href=\"https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2026-11-improving-access-to-treatments-in-the-community-for-trauma-and-medical-emergencies-and-ketamine-for-palliative-care\" target=\"_blank\">Consultation notification</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2025",
          "fs": "Dec 2025",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeP2AV"
          },
          "Id": "a0POZ00000WwQeP2AV",
          "Event_Date__c": "2025-12-01",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Links__c": "<p><a href=\"https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2026-11-improving-access-to-treatments-in-the-community-for-trauma-and-medical-emergencies-and-ketamine-for-palliative-care\" target=\"_blank\">Consultation notification</a></p>",
          "Formatted_Date__c": "Dec 2025",
          "Status_History__c": "a13OZ00000ZJKOfYAP"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2025",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2025",
          "fs": "Dec 2025",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000WwQeQ2AV"
          },
          "Id": "a0POZ00000WwQeQ2AV",
          "Event_Date__c": "2025-12-16",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Formatted_Date__c": "Dec 2025",
          "Status_History__c": "a13OZ00000ZJDGkYAP"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2025",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  }
]